FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2171198930> ?p ?o ?g. }

• W2171198930 endingPage "5861" @default.
• W2171198930 startingPage "5852" @default.
• W2171198930 abstract "Abstract Purpose: Immune responses to gene-modified cells are a concern in the field of human gene therapy, as they may impede effective treatment. We conducted 2 clinical trials in which cancer patients were treated with lymphocytes genetically engineered to express murine T-cell receptors (mTCR) specific for tumor-associated antigens p53 and gp100. Experimental Design: Twenty-six patients treated with autologous lymphocytes expressing mTCR had blood and serum samples available for analysis. Patient sera were assayed for the development of a humoral immune response. Adoptive cell transfer characteristics were analyzed to identify correlates to immune response. Results: Six of 26 (23%) patients' posttreatment sera exhibited specific binding of human anti-mTCR antibodies to lymphocytes transduced with the mTCR. Antibody development was found in both responding and nonresponding patients. The posttreatment sera of 3 of these 6 patients mediated a 60% to 99% inhibition of mTCR activity as measured by a reduction in antigen-specific interferon-γ release. Detailed analysis of posttreatment serum revealed that antibody binding was β-chain specific in 1 patient whereas it was α-chain specific in another. Conclusions: A subset of patients treated with mTCR-engineered T cells developed antibodies directed to the mTCR variable regions and not to the constant region domains common to all mTCR. Overall, the development of a host immune response was not associated with the level of transduced cell persistence or response to therapy. In summary, patients treated with mTCR can develop an immune response to gene-modified cells in a minority of cases, but this may not affect clinical outcome. Clin Cancer Res; 16(23); 5852–61. ©2010 AACR." @default.
• W2171198930 created "2016-06-24" @default.
• W2171198930 creator A5040016234 @default.
• W2171198930 creator A5058516855 @default.
• W2171198930 creator A5066867006 @default.
• W2171198930 creator A5069297078 @default.
• W2171198930 creator A5072133376 @default.
• W2171198930 creator A5078177020 @default.
• W2171198930 date "2010-12-01" @default.
• W2171198930 modified "2023-10-15" @default.
• W2171198930 title "Development of Human Anti-Murine T-Cell Receptor Antibodies in Both Responding and Nonresponding Patients Enrolled in TCR Gene Therapy Trials" @default.
• W2171198930 cites W1541816872 @default.
• W2171198930 cites W1570009082 @default.
• W2171198930 cites W1973177425 @default.
• W2171198930 cites W1976329054 @default.
• W2171198930 cites W1977917700 @default.
• W2171198930 cites W1987746867 @default.
• W2171198930 cites W1989467607 @default.
• W2171198930 cites W2011486273 @default.
• W2171198930 cites W2017304478 @default.
• W2171198930 cites W2038181190 @default.
• W2171198930 cites W2048164516 @default.
• W2171198930 cites W2050302632 @default.
• W2171198930 cites W2062361340 @default.
• W2171198930 cites W2064272625 @default.
• W2171198930 cites W2077200917 @default.
• W2171198930 cites W2079017842 @default.
• W2171198930 cites W2080692751 @default.
• W2171198930 cites W2094652659 @default.
• W2171198930 cites W2106083290 @default.
• W2171198930 cites W2107025688 @default.
• W2171198930 cites W2108131113 @default.
• W2171198930 cites W2121315503 @default.
• W2171198930 cites W2131398528 @default.
• W2171198930 cites W2136100686 @default.
• W2171198930 cites W2151246207 @default.
• W2171198930 cites W2163988610 @default.
• W2171198930 cites W2319534054 @default.
• W2171198930 doi "https://doi.org/10.1158/1078-0432.ccr-10-1280" @default.
• W2171198930 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3058233" @default.
• W2171198930 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21138872" @default.
• W2171198930 hasPublicationYear "2010" @default.
• W2171198930 type Work @default.
• W2171198930 sameAs 2171198930 @default.
• W2171198930 citedByCount "108" @default.
• W2171198930 countsByYear W21711989302012 @default.
• W2171198930 countsByYear W21711989302013 @default.
• W2171198930 countsByYear W21711989302014 @default.
• W2171198930 countsByYear W21711989302015 @default.
• W2171198930 countsByYear W21711989302016 @default.
• W2171198930 countsByYear W21711989302017 @default.
• W2171198930 countsByYear W21711989302018 @default.
• W2171198930 countsByYear W21711989302019 @default.
• W2171198930 countsByYear W21711989302020 @default.
• W2171198930 countsByYear W21711989302021 @default.
• W2171198930 countsByYear W21711989302022 @default.
• W2171198930 countsByYear W21711989302023 @default.
• W2171198930 crossrefType "journal-article" @default.
• W2171198930 hasAuthorship W2171198930A5040016234 @default.
• W2171198930 hasAuthorship W2171198930A5058516855 @default.
• W2171198930 hasAuthorship W2171198930A5066867006 @default.
• W2171198930 hasAuthorship W2171198930A5069297078 @default.
• W2171198930 hasAuthorship W2171198930A5072133376 @default.
• W2171198930 hasAuthorship W2171198930A5078177020 @default.
• W2171198930 hasBestOaLocation W21711989301 @default.
• W2171198930 hasConcept C104317684 @default.
• W2171198930 hasConcept C111599444 @default.
• W2171198930 hasConcept C121608353 @default.
• W2171198930 hasConcept C126322002 @default.
• W2171198930 hasConcept C147483822 @default.
• W2171198930 hasConcept C159654299 @default.
• W2171198930 hasConcept C19317047 @default.
• W2171198930 hasConcept C203014093 @default.
• W2171198930 hasConcept C2776090121 @default.
• W2171198930 hasConcept C2777701055 @default.
• W2171198930 hasConcept C55493867 @default.
• W2171198930 hasConcept C71924100 @default.
• W2171198930 hasConcept C86803240 @default.
• W2171198930 hasConcept C8891405 @default.
• W2171198930 hasConcept C90375314 @default.
• W2171198930 hasConceptScore W2171198930C104317684 @default.
• W2171198930 hasConceptScore W2171198930C111599444 @default.
• W2171198930 hasConceptScore W2171198930C121608353 @default.
• W2171198930 hasConceptScore W2171198930C126322002 @default.
• W2171198930 hasConceptScore W2171198930C147483822 @default.
• W2171198930 hasConceptScore W2171198930C159654299 @default.
• W2171198930 hasConceptScore W2171198930C19317047 @default.
• W2171198930 hasConceptScore W2171198930C203014093 @default.
• W2171198930 hasConceptScore W2171198930C2776090121 @default.
• W2171198930 hasConceptScore W2171198930C2777701055 @default.
• W2171198930 hasConceptScore W2171198930C55493867 @default.
• W2171198930 hasConceptScore W2171198930C71924100 @default.
• W2171198930 hasConceptScore W2171198930C86803240 @default.
• W2171198930 hasConceptScore W2171198930C8891405 @default.
• W2171198930 hasConceptScore W2171198930C90375314 @default.
• W2171198930 hasIssue "23" @default.
• W2171198930 hasLocation W21711989301 @default.
• W2171198930 hasLocation W21711989302 @default.

• next